Synthroid and Acetaminophen Interaction: What You Need to Know

Levothyroxine (brand names including Synthroid, a synthetic thyroid hormone, T4) and acetaminophen (brand name Tylenol, an analgesic and antipyretic) are two of the most commonly co-prescribed medications in adults with hypothyroidism. This article covers oral levothyroxine tablets and oral acetaminophen at over-the-counter and standard prescription doses, not injectable or compounded formulations of either drug.

The direct answer, and its boundary

For an adult with normal liver function taking levothyroxine at a stable dose and acetaminophen at standard analgesic doses, the FDA-approved Synthroid label does not list acetaminophen among the drugs known to reduce levothyroxine absorption or accelerate its clearance. That is a labeling-status statement, not a clinical trial result, and it should be read as "not flagged as a known interactor" rather than "proven interaction-free in every patient." Patients with hepatic impairment, chronic high-dose acetaminophen use, or an over-replaced thyroid state sit outside that reassurance and deserve individualized guidance from their prescriber or pharmacist.

Why this question comes up

Levothyroxine has a narrow therapeutic index, meaning small shifts in absorbed dose can move a patient from euthyroid to under- or over-replaced. The FDA-approved Synthroid prescribing information lists numerous drugs that interfere with levothyroxine absorption or metabolism, including calcium and iron salts, bile acid sequestrants, proton pump inhibitors, and enzyme-inducing anticonvulsants. Acetaminophen does not appear in that list. It does not contain the polyvalent cations that bind T4 in the gut, and it does not meaningfully change gastric pH.

The reason the question persists anyway is metabolic overlap rather than direct pharmacodynamic conflict. Both levothyroxine and acetaminophen are cleared in part through hepatic glucuronidation (UGT enzyme conjugation), and acetaminophen also undergoes a minor oxidative pathway through CYP2E1 that produces a reactive, potentially hepatotoxic metabolite (NAPQI) when the conjugation pathways are saturated. Shared enzyme families raise a theoretical competition question even when no clinical interaction has been demonstrated at ordinary doses.

What is established, what is plausible, what is not established

Established from FDA labeling and general pharmacology:

• Acetaminophen is not listed as a levothyroxine-interacting drug in the Synthroid label.
• Acetaminophen lacks the chelating cations that impair levothyroxine absorption.
• High-dose salicylates (aspirin, not acetaminophen) can displace thyroid hormone from serum binding proteins, a distinct and separately documented mechanism; this is a reason acetaminophen is often preferred over aspirin in patients on levothyroxine, though it is not itself evidence about acetaminophen.
• The FDA has restricted combination prescription products to 325 mg of acetaminophen per dose unit because of liver injury risk from acetaminophen overall, independent of levothyroxine, per an FDA drug safety communication.

Plausible but not established in humans on levothyroxine specifically:

• That an over-replaced (thyrotoxic) state increases CYP2E1 activity enough to meaningfully raise acetaminophen hepatotoxicity risk at standard doses. Animal data on thyroid status and acetaminophen-induced liver injury have been described in older pharmacology literature, but a direct human dose-response study in levothyroxine-treated patients has not been verified for this article and should be confirmed against current primary literature before being stated as fact.
• That chronic acetaminophen use near the daily ceiling meaningfully competes with levothyroxine for glucuronidation capacity in a way that changes TSH. This is a mechanistic inference from shared enzyme pathways, not a documented clinical finding.
• That older analog thyroid immunoassays could show falsely elevated free T4 after large acetaminophen doses. This has been described in older assay-interference literature; whether it applies to the assay platform used by a given lab today needs to be confirmed with the laboratory, since most modern labs use methods less prone to this artifact.

Not established:

• A defined dose threshold, in either drug, at which a clinically significant interaction begins.
• Any FDA warning, guideline statement from the American Thyroid Association, or systematic review specifically addressing levothyroxine plus acetaminophen as a distinct interaction pair (none was identified for this article; if one exists it should be added during editorial review).

Evidence-status interaction assessment

Who should be more cautious

Patients with liver disease. Cirrhosis, active hepatitis, or significant fatty liver disease reduce the safety margin for acetaminophen regardless of thyroid status. The FDA's acetaminophen dosing restrictions and general acetaminophen guidance reflect this independent of any levothyroxine interaction. These patients often need a lower acetaminophen ceiling, set by their prescriber, and may also need more frequent thyroid monitoring if hepatic changes affect drug clearance generally.

Patients who are currently over-replaced on levothyroxine. A suppressed TSH with elevated free T4 signals a thyrotoxic state. Whether this meaningfully raises acetaminophen hepatotoxicity risk in humans at standard analgesic doses is not established with confidence, but the mechanistic concern (increased CYP2E1 activity) is a reasonable basis for a clinician to check liver enzymes if this patient also uses acetaminophen regularly.

Patients using acetaminophen at or near the daily ceiling for chronic pain. At doses approaching 3,000 to 4,000 mg per day, the margin of safety narrows for reasons unrelated to levothyroxine (glucuronidation and sulfation pathways approach capacity). There is no published case report identified here documenting levothyroxine as a contributing factor in acetaminophen toxicity, but conservative dosing and periodic liver function checks are reasonable in this group regardless of thyroid medication use.

The practical timing rule

The clearest actionable guidance concerns absorption timing, and it is about levothyroxine's general sensitivity rather than anything specific to acetaminophen. The Synthroid label instructs patients to take the tablet on an empty stomach with water, then wait before eating or taking other medications. Following that same rule with acetaminophen, take levothyroxine first, wait roughly 30 to 60 minutes, then take acetaminophen, removes any theoretical absorption concern even though acetaminophen itself has not been shown to block levothyroxine absorption.

A verification checklist for clinicians and pharmacists

• Confirm the patient's total daily acetaminophen intake across all products, including combination cold, flu, and prescription pain medications, since acetaminophen is often hidden in these formulations.
• Confirm liver function status before assuming a routine acetaminophen ceiling is safe; adjust downward for known hepatic impairment or heavy alcohol use, per current FDA labeling for the specific acetaminophen product.
• Check the patient's most recent TSH and free T4. If the patient is currently over-replaced (suppressed TSH), consider a liver enzyme check if they are also a regular acetaminophen user, since this combination has plausible but unconfirmed added risk.
• If ordering thyroid function tests, ask when the patient last took a large dose of acetaminophen and confirm which assay method the lab uses, particularly if results seem inconsistent with the clinical picture.
• Do not assume "no known interaction" means "no monitoring needed" for patients outside normal hepatic function or stable TSH control.
• If citing a specific interaction severity rating from a drug-interaction database (Lexicomp, Micromedex, or similar), check the current version directly rather than relying on this article, since database classifications are updated over time.

What about NSAIDs or aspirin instead?

Acetaminophen has a different interaction profile with levothyroxine than aspirin does. High-dose aspirin (generally described in pharmacology literature as doses above roughly 2 grams per day) can displace thyroid hormone from serum binding proteins, transiently raising free T4 and potentially producing symptoms of over-replacement. This is a distinct, longer-established mechanism separate from anything discussed above for acetaminophen. NSAIDs such as ibuprofen also bind more competitively to albumin. For patients whose pain can be managed with acetaminophen, it is commonly used as a first-line analgesic in patients on levothyroxine, but this article does not have primary evidence to make a comparative safety ranking beyond the binding-displacement mechanism described here, and any patient-specific analgesic choice should come from their prescriber.

Special populations: what needs individual verification

Pregnancy. Levothyroxine requirements commonly increase during pregnancy, and dose adjustments are typically managed by the prescribing clinician with more frequent TSH checks. Acetaminophen is generally used as a preferred analgesic in pregnancy at standard doses, but any pregnancy-specific dosing or monitoring decision should come from the patient's obstetric or endocrine clinician rather than this article.

Older adults. Acetaminophen clearance can slow with age due to reduced hepatic blood flow, which is a reason some clinicians favor a lower ceiling in frail older adults regardless of thyroid status. Levothyroxine dosing targets in older adults sometimes allow a somewhat higher TSH than in younger adults, a decision that belongs to the prescriber based on the individual's cardiovascular and bone health profile.

Children. Weight-based acetaminophen dosing and age-appropriate levothyroxine dosing for congenital or acquired hypothyroidism are both established practices, but specific pediatric dosing must come from the child's pediatrician or endocrinologist, not from a general article. The fasting rule for levothyroxine still applies in children who can maintain a consistent morning routine.

When to seek urgent care

Anyone who has taken substantially more acetaminophen than the labeled daily maximum, intentionally or accidentally, needs urgent medical evaluation regardless of thyroid medication status, since acetaminophen overdose is a recognized cause of acute liver failure. New palpitations, significant heat intolerance, unexplained weight loss, or tremor in a patient on levothyroxine warrants a call to the prescriber to check for over-replacement, rather than self-adjusting either medication.

Evidence boundary summary

What is established: acetaminophen is not named as an interacting drug in the FDA Synthroid label, and it lacks the absorption-blocking properties of calcium, iron, and antacids. What is plausible but unproven: that thyrotoxicosis or chronic high-dose acetaminophen use meaningfully changes acetaminophen's hepatotoxicity risk or levothyroxine's clearance through shared glucuronidation pathways. What is not established: any specific dose threshold, case series, or guideline statement treating this pairing as a defined clinical interaction. Readers with liver disease, unstable thyroid levels, or chronic high-dose acetaminophen use should treat the reassuring general answer as provisional and confirm their own situation with a pharmacist or prescriber.